AIM: Febrile neutropenia (FN) is a highly prevalent complication of chemotherapy, particularly in patients with non-Hodgkin's lymphoma. This study aimed to compare the efficacy of filgrastim and pegfilgrastim in Asian lymphoma patients by evaluating the incidence of FN and associated complications. METHODS: This was a single-center, retrospective cohort study in Asian lymphoma patients who received chemotherapy with primary prophylactic granulocyte colony-stimulating factors support between January 2008 and August 2009. Data were analyzed using an intent-to-treat approach, which aimed to reflect actual prescribing practices. RESULTS: A total of 204 Asian lymphoma patients were included in this study, with 81 patients in the filgrastim arm and 123 patients in the pegfilgrastim arm. Overall, the incidence of breakthrough FN was similar between the two groups of patients (13.6%: filgrastim arm vs 16.3%: pegfilgrastim arm; P=0.69). Neutropenic complications such as chemotherapy treatment delay and chemotherapy dose reduction were similar between the two arms. CONCLUSION: In Asian patients, pegfilgrastim prophylaxis did not show a therapeutic advantage for preventing neutropenic outcomes compared with filgrastim prophylaxis.
AIM: Febrile neutropenia (FN) is a highly prevalent complication of chemotherapy, particularly in patients with non-Hodgkin's lymphoma. This study aimed to compare the efficacy of filgrastim and pegfilgrastim in Asian lymphomapatients by evaluating the incidence of FN and associated complications. METHODS: This was a single-center, retrospective cohort study in Asian lymphomapatients who received chemotherapy with primary prophylactic granulocyte colony-stimulating factors support between January 2008 and August 2009. Data were analyzed using an intent-to-treat approach, which aimed to reflect actual prescribing practices. RESULTS: A total of 204 Asian lymphomapatients were included in this study, with 81 patients in the filgrastim arm and 123 patients in the pegfilgrastim arm. Overall, the incidence of breakthrough FN was similar between the two groups of patients (13.6%: filgrastim arm vs 16.3%: pegfilgrastim arm; P=0.69). Neutropenic complications such as chemotherapy treatment delay and chemotherapy dose reduction were similar between the two arms. CONCLUSION: In Asian patients, pegfilgrastim prophylaxis did not show a therapeutic advantage for preventing neutropenic outcomes compared with filgrastim prophylaxis.
Authors: Alena M Pfeil; Kim Allcott; Ruth Pettengell; Gunter von Minckwitz; Matthias Schwenkglenks; Zsolt Szabo Journal: Support Care Cancer Date: 2014-10-07 Impact factor: 3.603
Authors: Claudio Cerchione; Lucio Catalano; Ilaria Peluso; Davide Nappi; Maria Di Perna; Dalila Salvatore; Ilaria Migliaccio; Marco Picardi; Fabrizio Pane Journal: Support Care Cancer Date: 2016-10-10 Impact factor: 3.603
Authors: Paul Cornes; Pere Gascon; Stephen Chan; Khalid Hameed; Catherine R Mitchell; Polly Field; Mark Latymer; Luiz H Arantes Journal: Adv Ther Date: 2018-10-08 Impact factor: 3.845